美罗培南与亚胺培南西司他丁钠用于重症肺炎治疗中的效果及安全性分析  

Effect and safety analysis of meropenem and imipenem-cilastatin sodium in the treatment of severe pneumonia

作　　者：李帅亿 LI Shuai-yi(The 991 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Xiangyang 441000,China)

机构地区：[1]中国人民解放军联勤保障部队第九九一医院,441000

出　　处：《中国现代药物应用》2025年第7期98-101,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨对比重症肺炎采用美罗培南与亚胺培南西司他丁钠治疗的效果及安全性。方法70例重症肺炎患者,以随机数字表法分为A组(采用美罗培南治疗)和B组(采用亚胺培南西司他丁钠治疗),各35例。对比两组疗效、血气指标[动脉血氧分压(PaO2)、血氧饱和度(SaO2)、氧合指数(OI)]、炎症指标[血清肿瘤坏死因子-α(TNF-α)、可溶性细胞间粘附分子-1(sICAM-1)、可溶性髓样细胞触发受体-1(sTREM-1)]、不良反应发生率。结果与B组治疗后总有效率82.86%对比,A组的97.14%明显更高(P<0.05)。治疗前,两组PaO2、SaO2、OI对比无明显差异(P>0.05);治疗后,两组PaO2、SaO2、OI均较治疗前升高,A组PaO2(87.42±2.96)mm Hg(1 mm Hg=0.133 kPa)、SaO2(97.14±2.05)%、OI(397.54±16.53)mm Hg比B组的(84.89±3.45)mm Hg、(95.32±2.68)%、(386.91±13.78)mm Hg明显更高(P<0.05)。治疗前,两组血清TNF-α、sICAM-1、sTREM-1对比无明显差异(P>0.05);治疗后,两组血清TNF-α、sICAM-1、sTREM-1均较治疗前降低,且A组血清TNF-α(16.31±1.94)ng/L、sICAM-1(195.82±15.76)μg/L、sTREM-1(33.52±5.86)ng/L低于B组的(20.68±2.49)ng/L、(226.93±17.52)μg/L、(37.91±6.52)ng/L(P<0.05)。与B组不良反应发生率17.14%对比,A组的2.86%明显更低(P<0.05)。结论美罗培南和亚胺培南西司他丁钠治疗重症肺炎均有较好的效果,但美罗培南疗效更高,有助于促进患者血气分析、炎症指标改善,减少不良反应,值得推广。Objective To explore and compare the effect and safety of meropenem and imipenem-cilastatin sodium in the treatment of severe pneumonia.Methods 70 patients with severe pneumonia were divided into group A(treated with meropenem)and group B(treated with imipenem-cilastatin sodium)by random numerical table,each with 35 cases.Both groups were compared in terms of curative effect,blood gas index[arterial partial pressure of oxygen(PaO2),oxygen saturation(SaO2),oxygenation index(OI)],inflammatory index[tumor necrosis factor-α(TNF-α),soluble inter-cellular adhesion molecule-1(sICAM-1),soluble triggering receptor expressed on myeloid cells-1(sTREM-1)],and incidence of adverse reactions.Results After treatment,the total effective rate of 97.14%in group A was significantly higher than 82.86%in group B(P<0.05).Before treatment,there were no significant differences in PaO2,SaO2 and OI between the two groups(P>0.05).After treatment,PaO2,SaO2 and OI in both groups were higher than those before treatment;group A had PaO2 of(87.42±2.96)mm Hg(1 mm Hg=0.133 kPa),SaO2 of(97.14±2.05)%and OI of(397.54±16.53)mm Hg,which were significantly higher than(84.89±3.45)mm Hg,(95.32±2.68)%and(386.91±13.78)mm Hg in group B(P<0.05).Before treatment,there were no significant differences in serum TNF-α,sICAM-1 and sTREM-1 between the two groups(P>0.05).After treatment,the serum TNF-α,sICAM-1 and sTREM-1 in both groups were lower than those before treatment;group A had serum TNF-αof(16.31±1.94)ng/L,sICAM-1 of(195.82±15.76)μg/L and sTREM-1 of(33.52±5.86)ng/L,which were lower than(20.68±2.49)ng/L,(226.93±17.52)μg/L and(37.91±6.52)ng/L in group B(P<0.05).Compared with 17.14%in group B,the incidence of adverse reactions in group A(2.86%)was significantly lower(P<0.05).Conclusion Both meropenem and imipenem-cilastatin sodium have good effects in the treatment of severe pneumonia,but meropenem has a higher curative effect,which helps promote patient blood gas analysis,improve inflammation indicators,reduce adverse reactions,and is wort

关 键 词：美罗培南 亚胺培南西司他丁钠 重症肺炎 血气分析 炎症反应 安全性 

分 类 号：R563.1[医药卫生—呼吸系统]